Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Top-Institutions - MDSpire

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • By

  • Yetian Dong

  • Tingting Yang

  • Mengyu Zhao

  • Fengmei Song

  • Rongrong Chen

  • Mingming Zhang

  • Ruimin Hong

  • Jingjing Feng

  • Shan Fu

  • Pingnan Xiao

  • Huijun Xu

  • Jiazhen Cui

  • Simao Huang

  • Guoqing Wei

  • Alex H. Chang

  • He Huang

  • Yongxian Hu

  • August 20, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #4

    Zhejiang University School of Medicine, First Affiliated Hospital
    Zhejiang University School of Medicine, First Affiliated Hospital

    Hangzhou, Zhejiang, China

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #5

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

Original Source(s)

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

  • August 20, 2025

Related Content

Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies

CLINICOPATHOLOGICAL FEATURES OF ADULT LYMPHOBLASTIC LYMPHOMA: A RETROSPECTIVE MULTICENTER STUDY FROM TÜRKİYE

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • by

  • February 9, 2026

  • 3 min